Should I buy or sell Delcath Systems stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCTH shares. View DCTH analyst ratings or view top-rated stocks .

What is Delcath Systems' stock price target for 2024?

4 analysts have issued 12-month price objectives for Delcath Systems' stock. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 293.6% from the stock's current price. View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts .

How have DCTH shares performed in 2024?

Delcath Systems' stock was trading at $4.16 at the beginning of the year. Since then, DCTH shares have increased by 13.0% and is now trading at $4.70. View the best growth stocks for 2024 here .

When is Delcath Systems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024. View our DCTH earnings forecast .

How were Delcath Systems' earnings last quarter?

Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19. The business earned $0.54 million during the quarter, compared to analysts' expectations of $0.48 million. Delcath Systems had a negative trailing twelve-month return on equity of 563.60% and a negative net margin of 2,308.86%. During the same quarter last year, the company earned ($0.86) earnings per share.

When did Delcath Systems' stock split?

Delcath Systems shares reverse split on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Delcath Systems?

Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:DCTH

Delcath Systems (DCTH) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free DCTH Stock Alerts

$4.71

+0.01 (+0.21%)

(As of 03:11 PM ET)

Compare

Today's Range: $4.62
▼
$4.78
50-Day Range: $3.72
▼
$5.09
52-Week Range: $2.25
▼
$7.99

Volume: 266,321 shs
Average Volume: 221,225 shs
Market Capitalization: $119.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.50

Get Delcath Systems alerts:

Delcath Systems MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 293.6% Upside
$18.50 Price Target
Short Interest: Bearish
3.68% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$100,001 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.45) to ($0.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.97 out of 5 stars

Medical Sector

432nd out of 918 stocks

Surgical & Medical Instruments Industry

46th out of 96 stocks

3.5

Analyst's Opinion

Consensus Rating
Delcath Systems has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Delcath Systems has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.68% of the outstanding shares of Delcath Systems have been sold short.
Short Interest Ratio / Days to Cover
Delcath Systems has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Delcath Systems has recently increased by 4.16%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Delcath Systems does not currently pay a dividend.
Dividend Growth
Delcath Systems does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DCTH.

2.2

News and Social Media Coverage

News Sentiment
Delcath Systems has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Delcath Systems this week, compared to 1 article on an average week.
Search Interest
5 people have searched for DCTH on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
7 people have added Delcath Systems to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Delcath Systems insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,001.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
21.10% of the stock of Delcath Systems is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.12% of the stock of Delcath Systems is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Delcath Systems are expected to grow in the coming year, from ($1.45) to ($0.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Delcath Systems is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Delcath Systems is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Delcath Systems has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Tips4Traders

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

[Click here to subscribe] and elevate your trading today.

About Delcath Systems Stock (NASDAQ:DCTH)

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

DCTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DCTH Stock News Headlines

March 21, 2024 | insidertrades.com

Insider Buying: Delcath Systems, Inc. (NASDAQ:DCTH) Director Acquires 26,882 Shares of Stock

April 16, 2024 | americanbankingnews.com

Head to Head Survey: Sharps Technology (NASDAQ:STSS) & Delcath Systems (NASDAQ:DCTH)

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

April 4, 2024 | finanznachrichten.de

Delcath Systems, Inc.: Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

April 4, 2024 | finance.yahoo.com

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)

March 27, 2024 | finance.yahoo.com

Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript

March 26, 2024 | finance.yahoo.com

Delcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancements

April 19, 2024 | Darwin (Ad)

2024's Must-Have Guide: Master Crypto Investment Today

March 26, 2024 | finanznachrichten.de

Delcath Systems, Inc.: Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 26, 2024 | msn.com

Delcath Systems GAAP EPS of -$0.48, revenue of $0.54M

March 26, 2024 | prnewswire.com

Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 25, 2024 | msn.com

Delcath Systems Q4 2023 Earnings Preview

March 23, 2024 | finance.yahoo.com

Insiders of Delcath Systems Getting Good Value On Their US$736.5k Investment

March 20, 2024 | prnewswire.com

Delcath Systems Closes $7 Million Private Placement

March 19, 2024 | prnewswire.com

Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call

March 19, 2024 | finanznachrichten.de

Delcath Systems, Inc.: Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

March 18, 2024 | markets.businessinsider.com

Delcath Systems Appoints Martha Rook As COO

March 18, 2024 | prnewswire.com

Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

March 17, 2024 | investing.com

Delcath Systems secures $7 million in private placement

March 16, 2024 | finance.yahoo.com

DCTH Apr 2024 7.500 call

March 15, 2024 | markets.businessinsider.com

Delcath Announces $7 Mln Private Placement

March 15, 2024 | prnewswire.com

Delcath Systems Announces $7 Million Private Placement

March 8, 2024 | prnewswire.com

Delcath Systems to Participate in Upcoming Investor Conferences

February 22, 2024 | stockhouse.com

Delcath Systems Announces Healthcare Setting Locator for HEPZATO(TM) KIT (melphalan/Hepatic Delivery System)

February 22, 2024 | finance.yahoo.com

Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

February 16, 2024 | prnewswire.com

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive DCTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Delcath Systems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/27/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:DCTH
CUSIP: N/A
CIK: 872912
Web: delcath.com
Phone: 212-489-2100
Fax: 212-489-2102
Employees: 76
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $18.50
High Stock Price Target: $21.00
Low Stock Price Target: $13.00
Potential Upside/Downside: +294.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-47,680,000.00
Net Margins: -2,308.86%
Pretax Margin: -2,308.86%
Return on Equity: -563.60%
Return on Assets: -111.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.26
Quick Ratio: 2.06

Sales & Book Value

Annual Sales: $2.07 million
Price / Sales: 57.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.72 per share
Price / Book: 6.52

Miscellaneous

Outstanding Shares: 25,440,000
Free Float: 20,071,000
Market Cap: $119.44 million
Optionable: Optionable
Beta: 0.53

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. Gerard J. Michel MBA (Age 61)
MS, CEO & Director
Comp: $671.6k
Dr. Johnny John M.D. (Age 59)
Senior Vice President of Clinical Operations & Medical Affairs
Comp: $472.16k
Ms. Sandra Pennell (Age 45)
Senior VP of Finance and Principal Financial & Accounting Officer
Dr. Martha S. Rook Ph.D. (Age 52)
Chief Operating Officer
Mr. David Hoffman
General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Vojislav Vukovic M.D. (Age 57)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DCTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Delcath Systems stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Delcath Systems in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCTH shares.
View DCTH analyst ratings or view top-rated stocks.
What is Delcath Systems' stock price target for 2024?: 4 analysts have issued 12-month price objectives for Delcath Systems' stock. Their DCTH share price targets range from $13.00 to $21.00. On average, they predict the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 293.6% from the stock's current price.
View analysts price targets for DCTH or view top-rated stocks among Wall Street analysts.
How have DCTH shares performed in 2024?: Delcath Systems' stock was trading at $4.16 at the beginning of the year. Since then, DCTH shares have increased by 13.0% and is now trading at $4.70.
View the best growth stocks for 2024 here.
When is Delcath Systems' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our DCTH earnings forecast.

How were Delcath Systems' earnings last quarter?: Delcath Systems, Inc. (NASDAQ:DCTH) posted its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.19. The business earned $0.54 million during the quarter, compared to analysts' expectations of $0.48 million. Delcath Systems had a negative trailing twelve-month return on equity of 563.60% and a negative net margin of 2,308.86%. During the same quarter last year, the company earned ($0.86) earnings per share.
When did Delcath Systems' stock split?: Delcath Systems shares reverse split on Tuesday, October 22nd 2019. The 1-100 reverse split was announced on Friday, October 18th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.
How do I buy shares of Delcath Systems?: Shares of DCTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DCTH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial